Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622
This examiner grants 89% of resolved cases
Justin Christopher Sanchez is an examiner in Tech Center 1600 and Art Unit 1622. The examiner has a record of 51 resolved cases. The allowance rate for these cases is 88.2 percent. This 88.2 percent rate indicates that a large majority of applications assigned to this examiner eventually reach allowance.
The interview lift for this examiner is 11.1 percent. This 11.1 percent lift suggests that interviews can provide a modest increase in the probability of success. The median days to allowance is 1212. This 1212-day period is an important consideration for practitioners when planning their prosecution strategy in Art Unit 1622. The 51 resolved cases provide the data necessary to understand the examiner's tendencies in Tech Center 1600.
Applicants can use the 1212 median days to allowance to estimate the time required to secure a patent. The 88.2 percent allowance rate serves as a strong indicator of the examiner's historical approach to applications. Furthermore, the 11.1 percent interview lift offers a data point for deciding whether to pursue direct communication during the examination process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18288550 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18530775 | SILYL-BIARYL PHOSPHORAMIDITES AND METHODS OF MAKING | Non-Final OA | Board of Regents, The University of Texas System |
| 17777909 | METHODS OF ADMINISTERING VOXELOTOR | Final Rejection | Global Blood Therapeutics, Inc. |
| 18713428 | OIL-BASED COSMETIC | Non-Final OA | SHISEIDO COMPANY, LTD. |
| 18571090 | SYNTHETIC PREPARATION FOR DIROXIMEL FUMARATE | Non-Final OA | BIOGEN MA INC. |
| 18296211 | AMORPHOUS AND CRYSTALLINE FORMS OF MCL-1 ANTAGONISTS | Non-Final OA | AMGEN INC. |
| 18376875 | COMBINED USE OF KETAMINE AND RETIGABINE (EZOGABINE) FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | Non-Final OA | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
| 18025315 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 17685892 | HISTONE DEACETYLASE AS A MODULATOR OF PDLI EXPRESSION AND ACTIVITY | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 17597631 | PROTEIN DEGRADERS AND USES THEREOF | Final Rejection | Kymera Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy